AML-464 Tolerability and Efficacy of the First-In-Class Anti-CD47 Antibody Magrolimab Combined With Azacitidine in Frontline Patients With TP53-Mutated Acute Myeloid Leukemia (AML): Phase 1b Results (2022)

First Author: Daver N
Attributed to:  Biology and Treatment of Human Myeloid Cancers funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1016/s2152-2650(22)01300-3

Publication URI: https://api.elsevier.com/content/abstract/scopus_id/85138131058

Type: Journal Article/Review

Parent Publication: Clinical Lymphoma Myeloma and Leukemia